← Search & browse all drugs
CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS › Angiotensin II receptor blockers (ARBs), other combinations
valsartan and aliskiren
C09DX02
Forms & Strengths
- Film-coated tablets: 150 mg/150 mg, 150 mg/300 mg, 300 mg/300 mg valsartan/aliskiren
- Tablets available in blister packs of 14, 28, 30, 56, 98, and 280
Adult Dosing
- Hypertension: 150 mg/150 mg once daily, titrate to 300 mg/300 mg as needed
- Diabetic nephropathy: 150 mg/150 mg once daily, adjust according to blood pressure response
- Maximum dose: 300 mg/300 mg once daily
Pediatric Dosing
- Not recommended for children under 18 years due to lack of data
- For pediatric patients with hypertension, alternative antihypertensive agents are recommended
Indications
- Treatment of essential hypertension
- Treatment of hypertension in patients with type 2 diabetes and diabetic nephropathy
Mechanism of Action
- Valsartan: Angiotensin II receptor antagonist, blocks vasoconstrictive effects of angiotensin II
- Aliskiren: Direct renin inhibitor, reduces Plasma Renin Activity and inhibits the conversion of angiotensinogen to angiotensin I
Contraindications
- Pregnancy and lactation
- Bilateral renal artery stenosis or unilateral stenosis in a solitary kidney
- Known hypersensitivity to valsartan or aliskiren
- Concomitant use with aliskiren in patients with diabetes
Adverse Reactions
- Hypotension, including orthostatic hypotension
- Dizziness, headache, fatigue
- Diarrhea, nausea, vomiting, abdominal pain
- Increased potassium levels, renal dysfunction
Drug Interactions
- Concomitant use with other ACE inhibitors or ARBs may increase the risk of hypotension, hyperkalemia, and renal dysfunction
- Furosemide: increased risk of hypotension
- Potassium-sparing diuretics: increased risk of hyperkalemia
- Lithium: increased risk of lithium toxicity
Curated Content: Needs Vetting Before Put to Clinical Use